CAC
AVIR icon

Certified Advisory Corp’s Atea Pharmaceuticals AVIR Stock Holding History

Certified Advisory Corp’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Hold
24,500
– – 0.01% 325
2026
Q1 		$132K Hold
24,500
– – 0.01% 315
2025
Q4 		$87.5K Hold
24,500
– – 0.01% 316
2025
Q3 		$71K Buy
+24,500
New +$83.7K 0.01% 313

Other funds holding AVIR

CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Certified Advisory Corp's AVIR Position: Q2 2026 in Review

Certified Advisory Corp held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 24,500 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #325.

Certified Advisory Corp first reported a position in AVIR in Q3 2025 and has held it in 4 quarters since. The position peaked at $132K in Q1 2026. 8 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Certified Advisory Corp held 24,500 shares of Atea Pharmaceuticals worth $114K as of Q2 2026.
  • Certified Advisory Corp left its Atea Pharmaceuticals share count unchanged in Q2 2026.
  • Atea Pharmaceuticals made up 0.01% of Certified Advisory Corp's portfolio in Q2 2026, its #325 holding.
  • Certified Advisory Corp first reported a position in Atea Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Certified Advisory Corp's Atea Pharmaceuticals position peaked at $132K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Certified Advisory Corp's 13F filing for Q2 2026, filed 16 Jul 2026.